Juliette Thariat

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 503 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement

David Thomson, David A. Palma, Matthias Gückenberger et al. · International Journal of Radiation Oncology*Biology*Physics · 2020 · 211 citations · Full text

Medicine, Oncology, Radiation Oncology +13

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO)

Thibaud Valentin, Axel Le Cesne, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2016 · 191 citations

Medicine, Oncology, Surgery +13

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer

Éric Lartigau, Emmanuelle Tresch, Juliette Thariat et al. · Radiotherapy and Oncology · 2013 · 181 citations

Medicine, Oncology, Radiation Oncology +7

Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database

Sébastien Salas, Noémie Resseguier, Jean‐Yves Blay et al. · Annals of Oncology · 2017 · 172 citations · Full text

Medicine, Clinical Sciences, Oncology +17